Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 55Carcinoma, Hepatocellular 40Neoplasms 38Polycystic Ovary Syndrome 27Colorectal Neoplasms 24Stomach Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Prostatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Recurrence 13Pancreatic Neoplasms 13Lymphoma 13Liver Neoplasms 13Urinary Bladder Neoplasms 11Leukemia, Myeloid, Acute 11Esophageal Neoplasms 11Leiomyoma 10Colonic Neoplasms 10Pain 9Lung Neoplasms 9Multiple Myeloma 8Uterine Cervical Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Keratosis, Actinic 7Infertility 7Papillomavirus Infections 6Pain, Postoperative 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Primary Breast Cancer × Clear all
NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Peking University

Phase 4 Unknown
304 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡